Results 61 to 70 of about 38,718 (192)

GLP-1 receptor agonists, carotid atherosclerosis and retinopathy [PDF]

Expert Opinion on Pharmacotherapy, 2017
It is known that diabetes is associated with the development of premature atherosclerosis and microvascular complications and consequently increased cardiovascular (CV) morbidity and mortality.
M. Rizzo, D. Nikolic, F. Di Pace, N. Papanas, N. Montano   +4 more
openaire   +3 more sources

Inhibition of Y1 receptor signaling improves islet transplant outcome [PDF]

, 2017
Failure to secrete sufficient quantities of insulin is a pathological feature of type-1 and type-2 diabetes, and also reduces the success of islet cell transplantation.
A Ali-Rachedi, A Thonpho, AD Nguyen, AG Nieuwenhuizen, AM Shapiro, AM Shapiro, American Diabetes, A., AR Saltiel, C Ammala, C Postic, C Ricordi, C Ricordi, CR Gustavsen, D Boey, D Boey, D Ize-Ludlow, DL Eizirik, DM Sousa, E Karra, G Bertrand, H Matsuda, H Yajima, HA Wieland, J Cantley, JM Sosenko, JY Kim, K Loh, K Yang, L Zhang, L Zhang, LA Selbie, M Jackerott, N Butta, O Idevall-Hagren, RA Stokes, RL Batterham, RP Robertson, S Kassis, S Seino, S Walters, T Yada, TL Belle van, TT Ngo, W Shao, Y Kashima, YC Shi, YC Shi   +46 more
core   +5 more sources

Challenging the Dogma: Reversal of End-Stage Liver Fibrosis with Tirzepatide in MASH Cirrhosis

Transplantology
Background/Objectives: The growing prevalence of metabolic-associated steatotic liver disease (MASLD)/metabolic-associated steatohepatitis (MASH) is forecasted to be over 55% by 2040, representing a significant driver of cirrhosis and highlighting demand
Thuy-Duyen Nguyen, Dora Lam-Himlin, Blanca Lizaola-Mayo, David Chascsa   +3 more
doaj   +1 more source

Rational Design by Structural Biology of Industrializable, Long-Acting Antihyperglycemic GLP-1 Receptor Agonists

Pharmaceuticals, 2022
Glucagon-like peptide-1 (GLP-1) is easily degraded by dipeptidyl peptidase-4 (DPP-4) in the human body, limiting its therapeutic effect on type II diabetes.
Lei Sun, Zhi-Ming Zheng, Chang-Sheng Shao, Zhi-Yong Zhang, Ming-Wei Li, Li Wang, Han Wang, Gen-Hai Zhao, Peng Wang   +8 more
doaj   +1 more source

Experiences with Glucagon-Like Peptide-1 Receptor Agonist in Children with Acquired Hypothalamic Obesity

Obesity Facts, 2020
Objective: Hypothalamic obesity (HO) in children after treatment for a tumor in the suprasellar region has severe implications. Previous studies have shown various effects of glucagon-like peptide-1 (GLP-1) receptor agonist in acquired HO, but in adults ...
Jiska van Schaik, Dominique G.A. Begijn, Laura van Iersel, Yvonne Vergeer, Eelco W. Hoving, Babette Peeters, Hanneke M. van Santen   +6 more
doaj   +1 more source

Combination GLP-1 and Insulin Treatment Fails to Alter Myocardial Fuel Selection Versus Insulin Alone in Type 2 Diabetes [PDF]

, 2018
Context Glucagon-like peptide-1 (GLP-1) and the clinically available GLP-1 agonists have been shown to exert effects on the heart. It is unclear whether these effects occur at clinically used doses in vivo in humans, possibly contributing to CVD risk ...
Considine, Robert V., Goodwill, Adam, Green, Mark A., Hamilton, LaTonya, Hutchins, Gary D., Mather, Kieren J., Mathias, Carla, Patel, Niral A., Territo, Wendy, Tune, Johnathan D.   +9 more
core   +1 more source

Favorable Appendicular Skeletal Muscle Mass Changes in Older Patients With Type 2 Diabetes Receiving GLP-1 Receptor Agonist and Basal Insulin Co-Therapy

Clinical Medicine Insights: Endocrinology and Diabetes, 2023
Background And Aims: Maintaining appendicular skeletal muscle mass is important for maintaining the quality of life of elderly patients with type 2 diabetes. The possibility of GLP-1 receptor agonists for maintaining appendicular skeletal muscle mass has
Takafumi Osaka, Masahide Hamaguchi, Michiaki Fukui   +2 more
doaj   +1 more source

A single extracellular amino acid in Free Fatty Acid Receptor 2 defines antagonist species selectivity and G protein selection bias [PDF]

, 2017
Free Fatty Acid Receptor 2 is a GPCR activated by short chain fatty acids produced in high levels in the lower gut by microbial fermentation of non-digestible carbohydrates.
Aoki, Junken, Bolognini, Daniele, Hansen, Anders Højgaard, Hudson, Brian D., Inoue, Asuka, Kawakami, Kouki, Kishi, Takayuki, Milligan, Graeme, Sergeev, Eugenia, Ulven, Trond   +9 more
core   +3 more sources

Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD [PDF]

Frontiers in Endocrinology, 2018
Along the obesity pandemic, the prevalence of non-alcoholic fatty liver disease (NAFLD), often regarded as the hepatic manifestation of the metabolic syndrome, increases worldwide representing now the prevalent liver disease in western countries. No pharmacotherapy is approved for the treatment of NAFLD and, currently, the cornerstone treatment is ...
Marta Seghieri, Marta Seghieri, Alexander S. Christensen, Andreas Andersen, Anna Solini, Filip K. Knop, Filip K. Knop, Filip K. Knop, Tina Vilsbøll, Tina Vilsbøll   +9 more
openaire   +6 more sources

Impact of exercise-nutritional state interactions in patients with type 2 diabetes

, 2020
Introduction This study examines the role of nutritional status during exercise training in patients with type 2 diabetes mellitus by investigating the effect of endurance-type exercise training in the fasted versus the fed state on clinical outcome ...
Calders, Patrick, Celie, Bert, Dendale, Paul, Hansen, Dominique, Lapauw, Bruno, Stevens, An, van Loon, Luc JC, Vandenabeele, Frank, Verboven, Kenneth, Wens, Inez   +9 more
core   +1 more source